Background: Micafungin (MCF) has shown poor removal by continuous renal replacement therapy (CRRT); however, it is not known whether candins can be removed by CVVHD-HCM. In critically ill patients with septic shock CVVHD-HCM have a potential benefit because it has a high cut-off membrane that purifies substances with molecular weight up to 45 kDa, including pro-inflammatory cytokines. Objective: to explore the pharmacokinetics of MCF in patients requering CVVHD-HCM.
Material/methods: On day 4 (steady state) of MCF therapy (100 mg/day) blood samples from arterial pre-filter, venous post-filter ports and drainage effluent samples were collected at the start and end of the infusion (1 hour) and at 4, 12 and 24 h. MCF concentrations were determined using HPLC. CVVHD-HCM was performed using polyarylethersulfone hemofilters (Septex®, Baxter S.L.). This study was funded by a research grant from Astellas
Results: MCF serum levels were obtained in 9 patients admitted in intensive care units receiving CVVHD-HCM and MCF for suspected or confirmed candidiasis. Median (range) age was 53.6 (28-80) years. Values for SOFA and Candida score in all patients were ≥ 8 and ≥ 4, respectively. Analysis obtained with the first 4 patients included in the study are shown in the next table:
Conclusions: Similar concentrations of MCF were obtained both in post-filter and in pre-filter ports. These findings, together with the practically undetectable levels of MCF in the effluent, pointed out that MCF is not significantly removed by the use of CVVH-HCM. The preliminary data of this study suggest that an adjustment of the MCF dose is not required in septic patients treated with CVVHD-HCM.